Kevin Grogan
Managing Editor, Europe
Covering all aspects of the pharma industry and across all therapeutic areas, Kevin has interviewed pretty much all the leading figures in the sector. A regular attendee at financial and medical conferences (and moderating at some), he has also appeared on BBC television and radio, ITV and Channel 4 to discuss the industry. Fluent in Spanish, he previously worked as a journalist on rock/pop music publications, was chief sub editor at Catholic newspaper The Universe and contributed articles to the likes of The Independent and the Manchester Evening News on football.
Latest From Kevin Grogan
Vicore ASPIREs To Be Major IPF Player As Sanofi Jumps Onboard
The Swedish company is well positioned, and well financed with a bit of help from the French major, to push its idiopathic pulmonary fibrosis hopeful buloxibutid closer to the regulatory finishing line.
FDA Backs Oryzon’s Phase III Plans For Borderline Personality Disorder Drug
Would-be partners for the Spanish firm’s vafidemstat will be closely following the news that regulators in the US are looking favorably on the LSD1 inhibitor’s potential as a therapy for the debilitating psychiatric illness.
Pentixapharm Poised To Make A Splash In The Radiopharmaceuticals Pool
The German group is spinning off from Eckert & Ziegler and listing in Frankfurt, though a leap to the NASDAQ will likely follow once it has more data on a lymphoma theranostic.
Merck & Co Takes A Punt On Evaxion’s AI Vaccines
Deal Snapshot: Merck likes the look of Evaxion's artificial intelligence-based technology platform to develop immunotherapies and signed a biobucks deal that will help ease the Copenhagen-headquartered biotech's financial situation.
Another Miss For LAG-3 In MSS Colorectal Cancer In Keytruda Combo Study
Nine months after Bristol Myers Squibb’s LAG-3/PD-L1 combination Opdualag failed a Phase III trial in microsatellite stable metastatic colorectal cancer, Merck & Co's fixed-dose combo of favezelimab and Keytruda has suffered the same fate in the indication.
UCB And Biogen Lifted By Promising Late-Stage Lupus Data
The clinical road has been pretty rocky for dapirolizumab pegol but a Phase III win is good news for the limited armamentarium of innovative treatments for lupus and a boost for Biogen’s hopes to expand its presence in immunology.